| Dr Lawrence M Schall, MD | |
|
815 S Garfield Ave, Alhambra, CA 91801 | |
| (626) 281-6268 | |
| (626) 281-9397 |
| Full Name | Dr Lawrence M Schall |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 39 Years |
| Location | 815 S Garfield Ave, Alhambra, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376651125 | NPI | - | NPPES |
| 00A429500 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | A42950 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emanate Health Foothill Presbyterian Hospital | Glendora, CA | Hospital |
| Entity Name | Lawrence M Schall, M.d., Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245429232 PECOS PAC ID: 8628007838 Enrollment ID: O20050808001293 |
News Archive
West Nile virus is an infection which in the last three years has had a significant impact in the United States. The virus is spread from birds to humans via mosquito bites. Symptoms include headache, fever and disorientation, and the disease can cause serious illness in a small percentage of infected people.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated September 16, 2009, from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market notifying Sunesis that it does not comply with the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2).
W. Christopher Risher, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a $399,600 grant from the National Institutes of Health for his research on the differences in brain development between males and females.
Lockheed Martin Corporation has completed its acquisition of QTC Holdings Inc. The company, based in Diamond Bar, Calif., is the largest provider of outsourced medical evaluation services to the U.S. Department of Veterans Affairs (VA), processing more than 450,000 evaluations last year.
A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lawrence M Schall, MD 815 S Garfield Ave, Alhambra, CA 91801 Ph: (626) 281-6268 | Dr Lawrence M Schall, MD 815 S Garfield Ave, Alhambra, CA 91801 Ph: (626) 281-6268 |
News Archive
West Nile virus is an infection which in the last three years has had a significant impact in the United States. The virus is spread from birds to humans via mosquito bites. Symptoms include headache, fever and disorientation, and the disease can cause serious illness in a small percentage of infected people.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated September 16, 2009, from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market notifying Sunesis that it does not comply with the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2).
W. Christopher Risher, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a $399,600 grant from the National Institutes of Health for his research on the differences in brain development between males and females.
Lockheed Martin Corporation has completed its acquisition of QTC Holdings Inc. The company, based in Diamond Bar, Calif., is the largest provider of outsourced medical evaluation services to the U.S. Department of Veterans Affairs (VA), processing more than 450,000 evaluations last year.
A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.
› Verified 6 days ago